Long-Term TRT: Risks, Benefits, and What to Monitor

Testosterone replacement therapy (TRT) is increasingly prescribed for men with clinically diagnosed hypogonadism — yet many patients and providers focus primarily on the short-term benefits without fully discussing the long-term picture. If you're on TRT or considering it, understanding the long-term risks, benefits, and monitoring requirements is essential for making informed decisions about your health.

Established Long-Term Benefits of TRT

For men with confirmed low testosterone (typically total testosterone below 300 ng/dL with symptoms), the evidence supports several sustained benefits of properly managed TRT:

Body Composition

Research consistently shows that TRT improves body composition over time. A meta-analysis published in Clinical Endocrinology found that long-term testosterone therapy was associated with sustained reductions in fat mass (approximately 3–5 kg) and increases in lean body mass. The Testosterone Trials (TTrials), a coordinated set of seven trials published in The New England Journal of Medicine, confirmed these findings in men over 65 with low testosterone.

Bone Mineral Density

Testosterone plays a critical role in bone health. The TTrials demonstrated that one year of testosterone treatment significantly increased bone mineral density and estimated bone strength, particularly in the spine and hip. Longer-term registry data from European studies suggest these improvements may be sustained with continued treatment.

Sexual Function and Libido

Improvements in libido and erectile function are among the most consistently reported benefits. The TRAVERSE trial — a large cardiovascular safety trial published in The New England Journal of Medicine in 2023 — confirmed that testosterone therapy improved sexual desire and erectile function compared to placebo over a median follow-up of approximately 33 months.

Mood and Energy

Many men report improved energy, mood, and overall quality of life on TRT. The TTrials found modest but significant improvements in mood and depressive symptoms. However, these benefits tend to plateau after the first 6–12 months, and TRT is not a substitute for mental health treatment when depression is the primary condition.

Potential Long-Term Risks

Cardiovascular Health

The cardiovascular safety of long-term TRT has been one of the most debated topics in endocrinology. The TRAVERSE trial — the largest randomized controlled trial of testosterone therapy to date, involving over 5,200 men aged 45–80 — found that testosterone therapy did not increase the rate of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo over the study period.

However, the trial did find a higher incidence of atrial fibrillation and acute kidney injury in the testosterone group, and follow-up was limited to approximately 33 months. Longer-term cardiovascular effects beyond this window remain uncertain. Men with existing cardiovascular risk factors should be monitored carefully.

Polycythemia (Elevated Red Blood Cells)

TRT stimulates erythropoiesis (red blood cell production), which can lead to polycythemia — an elevation in hematocrit levels. This is the most common dose-limiting side effect of long-term TRT. Elevated hematocrit increases blood viscosity and may raise the risk of thromboembolic events. Regular monitoring and dose adjustments are essential, and some patients may require periodic blood donation or phlebotomy.

Fertility Impact

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing or eliminating sperm production in most men. This effect is usually reversible upon discontinuation, but recovery can take 6–12 months or longer, and full recovery is not guaranteed. Men who wish to preserve fertility should discuss alternatives like enclomiphene or hCG with their provider before starting TRT.

Prostate Health

The relationship between TRT and prostate cancer has been a longstanding concern. Current evidence, including data from the TRAVERSE trial, has not shown that TRT increases the incidence of prostate cancer. However, testosterone can stimulate growth of existing prostate cancer, making screening with PSA and digital rectal exam important before and during therapy. TRT is generally contraindicated in men with known prostate cancer.

Essential Monitoring on Long-Term TRT

Responsible long-term TRT requires regular monitoring. Most clinical guidelines, including those from the American Urological Association and the Endocrine Society, recommend the following:

• Testosterone levels: Checked 3–6 months after initiation and periodically thereafter to ensure levels are within the target range (typically 400–700 ng/dL).
• Hematocrit/hemoglobin: Monitored every 6–12 months. Hematocrit above 54% typically requires dose reduction or phlebotomy.
• PSA (Prostate-Specific Antigen): Baseline and periodic screening, particularly in men over 40.
• Lipid panel: TRT can affect HDL cholesterol levels. Regular lipid monitoring is important for cardiovascular risk assessment.
• Liver function: Particularly relevant for oral testosterone formulations.
• Estradiol: Testosterone converts to estradiol via aromatase. Monitoring helps manage potential side effects like gynecomastia.
• Bone density: DEXA scans may be appropriate in men who had low bone density at baseline.

Discontinuing TRT: What to Expect

Stopping TRT after long-term use requires planning. The HPG axis may take weeks to months to recover, during which time symptoms of low testosterone typically return. Some men experience a "rebound" period with worse symptoms than baseline before levels normalize. Gradual tapering and use of agents like clomiphene to stimulate endogenous production may help ease the transition, but this should always be done under provider supervision.

The Bottom Line

Long-term TRT can provide sustained improvements in body composition, bone health, sexual function, and quality of life for men with confirmed hypogonadism. However, it requires ongoing medical supervision, regular lab monitoring, and honest conversations about potential risks — particularly regarding polycythemia, fertility, and cardiovascular health. The TRAVERSE trial has provided important reassurance regarding cardiovascular safety, but questions about very long-term outcomes remain.

The key to safe, effective long-term TRT is an informed patient working with a knowledgeable provider who monitors treatment appropriately and adjusts as needed over time.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment or supplement.